Top stories in gastroenterology: Drugs for ulcerative colitis show promise, ‘imposter syndrome’ effects on female practitioners

The top stories in gastroenterology this week all come from the Digestive Disease Week meeting, which wrapped up on June 5 in Washington, D.C.

One presentation demonstrated mirikizumab showed efficacy when treating patients with moderate-to-severe ulcerative colitis. Another presentation showed closing mucosal defects after the removal of colorectal polyps using an endoscopic clip effectively reduced incidence of delayed bleeding events and other complications.

Other top stories include data that suggests Xeljanz is safe for long-term ulcerative colitis, women in medicine are more likely to suffer from “imposter syndrome,” and how the investigational anti-interleukin 15 inhibitor known as AMG 715showed safety and efficacy for halting the progression of refractory celiac disease II. – by Jake Scott

Mirikizumab shows efficacy in moderate-to-severe ulcerative colitis

Data reveal that mirikizumab, an anti-interleukin-23 therapy developed by Eli Lilly,showed efficacy in treating patients with moderate-to-severe ulcerative colitis. Read more.

Endoscopic clip reduces delayed bleeding events after polyp resection

Closing mucosal defects following the removal of large colorectal polyps using an endoscopic clip was effective in reducing the incidence of delayed bleeding events and other complications, researchers said. Read more.

Xeljanz appears safe for long-term ulcerative colitis treatment despite herpes zoster risk

Xeljanz, an oral small molecule Janus kinase inhibitor recently approved for ulcerative colitis, showed “an overall manageable safety profile” at up to 4.4 years in patients with the condition, although there was a dose-dependent risk for herpes zoster, according to OCTAVE study data. Read more.

‘Imposter syndrome’ prevalent among women in medicine, but can be overcome

Many women in medicine, despite their high performance and success, have a pervasive feeling that they are professionally successful because of hard work and chance, not because they are intelligent, according to a gastroenterology and hepatology expert. Read more.

IL-15 inhibitor shows promise in halting progression of refractory celiac disease type II

AMG 715, an investigational anti-interleukin 15 inhibitor, showed safety and efficacy for stopping the progression of refractory celiac disease type II, phase 2 randomized controlled trial data show. Read more.